Effect of uric acid on inflammatory COX-2 and ROS pathways in vascular smooth muscle cells

References

• Kopel E. Serum uric acid and cardiovascular risk: an early wake-up call. J Adolesc Health. 2015;56:363–364.
   PubMed Web of Science ®Google Scholar
• Katsiki N, Mikhailidis DP. Hyperuricaemia in cardiovascular diseases: a passive or an active player? Med Princ Pract. 2015;24:269–270.
   PubMed Web of Science ®Google Scholar
• Jin M, Yang F, Yang I, et al. Uric acid, hyperuricemia and vascular diseases. Front Biosci. 2012;17:656–669.
   PubMed Web of Science ®Google Scholar
• Kanellis J, Watanabe S, Li JH, et al. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension. 2003;41:1287–1293.
   PubMed Web of Science ®Google Scholar
• Kang DH, Han L, Ouyang X, et al. Uric acid causes vascular smooth muscle cell proliferation by entering cells via a functional urate transporter. Am J Nephrol. 2005;25:425–433.
   PubMed Web of Science ®Google Scholar
• Baker CS, Hall RJ, Evans TJ, et al. Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. Arterioscler Thromb Vasc Biol. 1999;19:646–655.
   PubMed Web of Science ®Google Scholar
• Dubois RN, Abramson SB, Crofford L, et al. Cyclooxygenase in biology and disease. FASEB J. 1998;12:1063–1073.
   PubMed Web of Science ®Google Scholar
• Pritchard KA Jr, O’Banion MK, Miano JM, et al. Induction of cyclooxygenase-2 in rat vascular smooth muscle cells in vitro and in vivo. J Biol Chem. 1994;269:8504–8509.
   PubMed Web of Science ®Google Scholar
• Ohnaka K, Numaguchi K, Yamakawa T, et al. Induction of cyclooxygenase-2 by angiotensin II in cultured rat vascular smooth muscle cells. Hypertension. 2000;35:68–75.
   PubMed Web of Science ®Google Scholar
• Xu K, Kitchen CM, Shu HK, et al. Platelet-derived growth factor-induced stabilization of cyclooxygenase 2 mRNA in rat smooth muscle cells requires the c-Src family of protein-tyrosine kinases. J Biol Chem. 2007;282:32699–32709.
   PubMed Web of Science ®Google Scholar
• Kang DH, Nakagawa T, Feng L, et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol. 2002;13:2888–2897.
   PubMed Web of Science ®Google Scholar
• Hayden MR, Tyagi SC. Uric acid: a new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: the urate redox shuttle. Nutr Metab. 2004;1:10.
   Google Scholar
• Ishizaka Y, Yamakado M, Toda A, et al. Relationship between serum uric acid and serum oxidative stress markers in the Japanese general population. Nephron Clin Pract. 2014;128:49–56.
   PubMedGoogle Scholar
• Clempus RE, Griendling KK. Reactive oxygen species signaling in vascular smooth muscle cells. Cardiovasc Res. 2006;71:216–225.
   PubMed Web of Science ®Google Scholar
• Sautin YY, Nakagawa T, Zharikov S, et al. Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. Am J Physiol Cell Physiol. 2007;293:11.
   Web of Science ®Google Scholar
• Corry DB, Eslami P, Yamamoto K, et al. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens. 2008;26:269–275.
   PubMed Web of Science ®Google Scholar
• Cetin A, Ozturk OH, Tokay A, et al. Angiotensin II-induced MAPK phosphorylation mediated by Ras and/or phospholipase C-dependent phosphorylations but not by protein kinase C phosphorylation in cultured rat vascular smooth muscle cells. Pharmacology. 2007;79:27–33.
   PubMed Web of Science ®Google Scholar
• Görlach A, Brandes RP, Bassus S, et al. Oxidative stress and expression of p22phox are involved in the up-regulation of tissue factor in vascular smooth muscle cells in response to activated platelets. FASEB J. 2000;14:1518–1528.
   PubMed Web of Science ®Google Scholar
• Zoccali C, Maio R, Mallamaci F, et al. Uric acid and endothelial dysfunction in essential hypertension. J Am Soc Nephrol. 2006;17:1466–1471.
   PubMed Web of Science ®Google Scholar
• Kirca M, Oguz N, Cetin A, et al. Uric acid stimulates proliferative pathways in vascular smooth muscle cells through the activation of p38 MAPK, p44/42 MAPK and PDGFRbeta. J Recept Sig Transd Res. 2017;37:167–173.
   PubMed Web of Science ®Google Scholar
• Paravicini TM, Touyz RM. Redox signaling in hypertension. Cardiovasc Res. 2006;71:247–258.
   PubMed Web of Science ®Google Scholar
• Sautin YY, Nakagawa T, Zharikov S, et al. Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. Am J Physiol Cell Physiol. 2007;293:C584–C596.
   PubMed Web of Science ®Google Scholar
• Hoieggen A, Alderman MH, Kjeldsen SE, et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int. 2004;65:1041–1049.
   PubMed Web of Science ®Google Scholar
• Culleton BF, Larson MG, Kannel WB, et al. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med. 1999;131:7–13.
   PubMed Web of Science ®Google Scholar
• Patetsios P, Song M, Shutze WP, et al. Identification of uric acid and xanthine oxidase in atherosclerotic plaque1. Am J Cardiol. 2001;88:188–191.
   PubMed Web of Science ®Google Scholar
• Sanchez-Lozada LG, Nakagawa T, Kang DH, et al. Hormonal and cytokine effects of uric acid. Curr Opin Nephrol Hypertens. 2006;15:30–33.
   PubMed Web of Science ®Google Scholar
• Fauvel JP, Velon S, Berra N, et al. Effects of losartan on renal function in patients with essential hypertension. J Cardiovasc Pharmacol. 1996;28:259–263.
   PubMed Web of Science ®Google Scholar
• Hamada T, Ichida K, Hosoyamada M, et al. Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients. Am J Hypertens. 2008;21:1157–1162.
   PubMed Web of Science ®Google Scholar
• Young W, Keyman M, Haider A, et al. Cyclooxygenase-2 is required for tumor necrosis factor-alpha- and angiotensin II-mediated proliferation of vascular smooth muscle cells. Circ Res. 2000;86:906–914.
   PubMed Web of Science ®Google Scholar